Epidermal Growth Factor Receptor Mutant T790M-L858R-V948R Inhibitor from Calophyllum Inophyllum L. Leaf as Potential Non-Small Cell Lung Cancer Drugs

    Precella Silvia, Jeremi Ongko, Yulanda Antonius
    Image of study
    TLDR A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
    The study aimed to identify potential inhibitors of an epidermal growth factor receptor (EGFR) mutant from Calophyllum inophyllum L. leaf for treating non-small cell lung cancer (NSCLC). Using in silico analysis, the compound 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl was identified as a non-toxic candidate with low binding affinity to the EGFR mutant protein. This compound interacts with key amino acid residues, inhibiting ATP binding to the tyrosine kinase domain, thus potentially inhibiting the EGFR mutant. Further in vitro and in vivo research is necessary to confirm these findings.
    Discuss this study in the Community →